UK
Mental health spending varies dramatically among regions in England, analysis shows
May 14, 2019Manufacturing and Production England, NHS, UK, mental health, mind, spending
Spending on mental health varies dramatically between regions in England, according to analysis from mental health charity Mind. South Yorkshire …
UK GPs are underequipped to handle growing chronic opioid use, report warns
May 13, 2019Medical Communications, Sales and Marketing NHS, UK, opioid crisis, opioids, pharma
New research from the University of East Anglia (UEA) has argued that general practitioners (GPs) in the UK are lacking …
Heart disease deaths increase for first time in 50 years
May 13, 2019Sales and Marketing BHF, UK, cardiovascular, health, heart disease, obesity
Deaths from heart disease among people under the age of 75 have increased for the first time in 50 years. …
Ocrevus becomes first NICE-approved therapy on the NHS for primary progressive multiple sclerosis
May 9, 2019Sales and Marketing Genentech, NHS, NICE, Ocrevus, UK
NICE has announced its final appraisal decision on Genentech’s Ocrevus (ocrelizumab), choosing to recommend the drug for use on the …
US prescription drugs most expensive in world, analysis shows
May 8, 2019Research and Development Drug pricing, Japan, Ontario, UK, US, prescription drugs
Brand name prescription drugs cost on average 4.3 times more in the United States than in the UK, according to …
Will mobile phones save the NHS?
May 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, UK, feature, mhealth, mobile health, pharma
The NHS is sick. According to politicians and NHS chiefs, the cure involves a strong dose of mHealth. Louis Goss …
Two thirds of MPs believe NHS should spend less on medicines
April 30, 2019Manufacturing and Production Long Term Plan, MPs, NHS, UK, government, health, public health
Nearly two thirds (64%) of MPs believe the NHS should direct more resources towards prevention, over funding for new treatments, …
The price of access: Can the NHS afford Orkambi?
April 29, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, NHS, NICE, Orkambi, UK, Vertex, access, cystic fibrosis, feature, pharma, pricing
The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in …
NICE recommends UCB’s Cimzia in severe plaque psoriasis
April 18, 2019Sales and Marketing Cimzia, NICE, UCB Pharma, UK, pharma, plaque psoriasis, psoriasis
NICE has announced its decision to recommend UCB Pharma’s Cimzia (certolizumab pegol) for use on the NHS in England in …
NICE recommends Akcea’s Tegsedi for rare, life-threatening progressive disease
April 17, 2019Research and Development, Sales and Marketing Akcea, NHS, NICE, Tegsedi, UK
Akcea Therapeutics has shared the news that Tegsedi (inotersen), its antisense oligonucleotide (ASO) inhibitor of human transthyretin (TTR) production, has …
Reckitt Benckiser to unveil £105 R&D site in Hull by end of June
April 11, 2019Manufacturing and Production Hull, R&D, Reckitt Benckiser, UK, pharma
Reckitt Benckiser (RB) has announced that its £105 million research and development facility in the UK city of Hull – …
Epilepsy Society calls for review of UK supply chain following “steep rise” in access issues
April 9, 2019Manufacturing and Production, Sales and Marketing Epilepsy Society, UK, brexit, epilepsy, market access, pharma
The Epilepsy Society has drawn attention to the “steep rise” in UK patients who are encountering difficulty in accessing seizure …
Eisai and MSD’s Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer
April 8, 2019Manufacturing and Production, Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, liver cancer, pharma
Patients in Scotland with with advanced or unresectable hepatocellular carcinoma (HCC) will now be able to access Eisai and MSD’s …
NICE turns down Astellas’ Xtandi in prostate cancer
April 8, 2019Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer
Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
